Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2022 | Story Prof Felicity Burt, Prof Dominique Goedhals and Dr Charles Kotzé
Prof Felicity Burt, Dr Charles Kotze and Prof Dominique Goedhals
From the left; Prof Felicity Burt, Dr Charles Kotzé and Prof Dominique Goedhals.

Opinion article by Prof Felicity Burt , Prof Dominique Goedhals , Division of Virology at the University of the Free State (UFS), and Dr Charles Kotzé, National Health Laboratory Service (NHLS), Universitas Academic Hospital.
The recent COVID-19 pandemic has certainly highlighted the importance of vigilance and awareness of emerging diseases with public health implications. The monkeypox virus has recently made headlines, after the detection of more than 200 cases in geographically distinct regions. On 13 May, the World Health Organisation (WHO) was notified of human cases of the monkeypox disease occurring in the United Kingdom, outside of the known endemic region.

Exported cases have been detected previously and usually occur sporadically. In contrast, within the past two weeks, human cases have been confirmed in at least 21 countries, including various European countries, the United Kingdom, Israel, the Canary Islands, Canada and the United States, and Australia. The initial case appears to have been a traveller from Nigeria. Sequence data may help to determine if there have been multiple exportations from West Africa. 

What is monkeypox and what do we know

What is monkeypox and what do we know about the aetiologic agent? Monkeypox is the name given to a disease caused by the monkeypox virus, a zoonotic pathogen endemic in Central and West Africa and responsible for cases of the disease in the endemic region, with occasional exported cases in travellers. The virus was initially identified in 1958 in monkeys housed at a research laboratory in Denmark, and the name monkeypox was derived from the appearance of lesions and the occurrence in monkeys. The first human case was identified 52 years ago in the Democratic Republic of the Congo. Since then, human monkeypox cases have been reported in several other Central and West African countries: Cameroon, the Central African Republic, Ivory Coast, the Democratic Republic of the Congo, Gabon, Liberia, Nigeria, Republic of the Congo, and Sierra Leone. The first monkeypox outbreak outside of Africa was in the United States of America in 2003 and was linked to contact with infected prairie dogs imported as exotic pets. Since then, there have been various small, contained outbreaks outside of Africa that have mostly been linked to the importation of the virus from African countries. 

The virus is related to the smallpox virus, which was eradicated in the 1970s by vaccination. Although belonging to the same family of viruses as the smallpox virus, the disease caused by monkeypox is less severe, with fewer fatalities.   Unlike smallpox, which carries a case fatality rate of 30%, the case fatality rate in monkeypox is low (estimated at 3-6% in more recent outbreaks).  There are two clades of the monkeypox virus: the West African clade and the Congo Basin (Central African) clade. In this outbreak, all of the cases have been linked to the West African clade of the monkeypox virus.

Transmission occurs from animal to human, and from human to human, through close contact with lesions, body fluids, and contaminated materials. The virus enters the body through the respiratory tract, mucous membranes, or broken skin.  The disease begins with non-specific symptoms such as fever, headache, muscle pains, and swollen lymph nodes. This is followed by the typical skin rash, which progresses through stages known as macules, then papules, vesicles, pustules, and lastly crusts or scabs. Lesions can also occur on mucous membranes such as the mouth, eye, and genital area.  The infectious period lasts through all stages of the rash, until all the scabs have fallen off. There are a number of other infectious and non-infectious conditions that need to be differentiated; therefore, individuals presenting with these symptoms will need to consult their doctor to determine whether a diagnosis of monkeypox needs to be considered. In the current outbreak, a number of the cases in the United Kingdom and Europe have been detected in men who have sex with men, during visits to sexual health clinics. This pattern of spread has not previously been described and it remains to be determined whether the spread has occurred through close person-to-person contact or through sexual transmission.  

Vaccination against smallpox virus offers 85% protection against monkeypox

To date, no cases have been detected in South Africa, but the recent global spread of the severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2) highlights the ability of pathogens to spread. The National Institute for Communicable Diseases (NICD) in Johannesburg offers a specialised diagnostic service for the monkeypox virus, using molecular assays and electron microscopy. 

Vaccination against the smallpox virus is believed to offer 85% protection against monkeypox, hence older persons should have some protection; however, vaccination against smallpox was phased out globally following the eradication of smallpox during the 1970s. A more recently developed vaccine against monkeypox is available but has very limited availability.  No specific antivirals are available with proven efficacy in clinical trials.

While the monkeypox virus can be spread via the respiratory route, this occurs in the form of large droplets, rather than aerosol transmission, which is seen with SARS-CoV-2 (causing COVID-19). Aerosols are smaller particles that can remain suspended in the air for prolonged periods, facilitating the transmission of SARS-CoV-2. Monkeypox is therefore less contagious than COVID-19, as close contact is required for longer periods.  For this reason, many experts around the world predict that this outbreak will not spread like SARS-CoV-2. The importation of monkeypox to South Africa is a definite possibility, because South Africa is a significant economic and travel hub for Africa. Previous outbreaks of monkeypox in non-endemic areas have been interrupted by contact tracing and isolation, which was very effective in controlling further spread.  Heightened vigilance is therefore needed for the early detection of such cases.

News Archive

Dr Karen Lazenby appointed as Registrar: Systems and Administration
2015-11-11


Dr Karen Lazenby, Registrar: Systems and Administration

Dr Karen Lazenby, former Director: Client Service Centre at the University of Pretoria (UP), was appointed as Registrar: Systems and Administration at the University of the Free State (UFS) as from 1 November 2015. She will be responsible for student enrolment, administration and services, and International Affairs.

“We are extremely fortunate to have a person of the calibre and experience of Dr Lazenby to join the senior team to help us create a 21st century student-centred management system using the best technologies available. She is without question the leader in her field, and the UFS is delighted to have her as part of the Kovsie community,” says Prof Jonathan Jansen, Vice-Chancellor and Rector of the UFS.

Educational background

Dr Lazenby completed the BA (1992) and Honours (1993) degrees in English (cum laude) at the University of Potchefstroom before pursuing a Diploma in Tertiary Education (1996) and a Master's Degree in Computer Integrated Education (1998) at the University of Pretoria. She obtained a PhD in Education in 2003 on the topic ‘Technology and educational innovation: A case study of the virtual campus of the University of Pretoria’ and an Executive MBA from the University of Cape Town in 2006.

A track record to reckon with


Dr Lazenby started her career in higher education as a lecturer in Communication at the VaalTriangle Technikon in 1994, and was appointed as Head of Academic Staff Development the following year.  A year later, she joined Technikon SA as instructional designer at the Centre for Courseware Design and Development, and in 1997 she was appointed as Manager of Institutional Research. She was subsequently seconded to establish TSA Online and coordinate institutional technology. Dr Lazenby was appointed as a project manager at the department of Education Innovation at the University of Pretoria in 1998 where she implemented WebCT/Blackboard, online applications and payments, and student and lecturer portals (virtual campus). In 2000 she was appointed as Deputy Director: Electronic Education.

She was seconded by the UP Executive to establish the Client Service Centre in 2001 to provide integrated, efficient and effective services to students and other clients of the University. During her time as Director: Client Service Centre, she was inter alia, responsible for information and data governance, the intranet, website and call centre of the university, student recruitment, publications, application for study support, study finance, postgraduate scholarships, student accounts, payments, residence placement, access cards and parking, the graduate career office, and international student division. In 2005, she also acted as Director: Corporate Communication and Marketing.

Her vision for the UFS

“I would like to get the university's student administration to such a point that academic staff can focus on teaching and research. Streamlining the enrolment process so that we may see the necessary yield required in terms of our growth target as a university, is my other goal.” She added that capitalising on the strong international positioning of the UFS achieved by Prof Jansen, is a mission she intends to carry out. "I am grateful for the opportunity to work with Prof Jansen and the senior management team and am delighted to be part of the Kovsie community."

Dr Lazenby has published several articles and presented nineteen papers at international conferences.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept